RUNX3 and colorectal cancer: Ogino et al. found that patients with metastatic, microsatellite stable colorectal cancer with hypermethylated RUNX3 had an impaired prognosis when receiving combination chemotherapy compared to patients with unmethylated RUNX3 [41].